1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
JW Holdings Corporation

JW Holdings Corporation

KKRX:096760
3,900.00
KRW
-45.00
(-1.14%)
2,260.73EPS
3.02P/E
254.28BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8,142.82
8,397.24
8,623.27
9,795.14
9,436.31
10,008.37
9,863.51
10,597.61
11,081.86
11,961.58
12,926.28
12,390.41
13,937.39
14,589.55
Basic EPS, GAAP
273.61
-160.06
2.51
-123.91
748.59
319.68
-388.49
122.91
-39.03
306.49
265
874
841
1,218.52
Free Cash Flow per Basic Share
-1,071.09
-491.39
-510.15
-632.26
-210.02
2,347.88
965.81
694.55
928.43
474.81
376.24
867.98
1,566.42
2,215.96
Dividend per Share
60.49
60.23
56.64
103.03
140.67
297.79
211.74
216.99
203.41
213.34
247.1
239.66
266.32
-1.67
Book Value per Share
1,617.83
1,442.33
1,542.02
1,598.84
2,292.28
2,509.21
1,463.49
1,521.96
1,328.94
1,480.61
1,749.94
3,247.67
3,858.35
4,190.85
Tangible Book Value per Share
15.2
-202.75
-18.21
217.13
-391.22
-104.05
-1,268.26
-980.62
-1,234.37
-917.08
-296.57
41.16
292.54
569.86
Basic Weighted Avg Shares
65
68
72
70
72
72
74
74
71
72
72
72
70
69
Sales/Revenue/Turnover
530,263
573,920
622,825
684,839
680,970
725,366
728,082
781,515
788,937
864,536
928,072
887,710
969,565
1,011,343
Operating Margin (%)
3.85
3.18
5.37
6.33
6.1
4.59
0.83
4.78
8.71
13.11
15.66
16.53
17.32
18.82
Depreciation Expense
25,405
20,270
21,718
22,226
32,026
34,962
41,574
42,910
38,383
40,126
44,222
41,089
43,643
44,846
Net Income, GAAP
17,817
-10,940
181
-8,663
54,022
23,169
-28,676
9,064
-2,778
22,152
19,026
62,618
58,505
84,468
Effective Tax Rate (%)
24.74
- -
- -
226.3
0.08
1,696.5
- -
85.65
86.35
34.53
41.89
22.35
19.94
11.87
Profit Margin (%)
3.36
-1.91
0.03
-1.27
7.93
3.19
-3.94
1.16
-0.35
2.56
2.05
7.05
6.03
8.35
Working Capital
-108,872
-11,417
-22,176
84,049
57,269
142,217
-77,488
-146,833
-50,084
-207,831
-233,306
-43,504
-55,818
-109,292
LT Debt
106,590
215,274
157,889
213,287
252,263
239,955
163,779
89,670
211,257
73,593
42,482
170,341
101,247
17,080
Total Equity
236,025
207,756
270,306
277,591
370,603
400,997
335,294
324,351
304,823
333,263
348,755
521,395
594,627
645,688
Return on Invested Capital (%)
1.77
- -
- -
-6.11
4.22
-51.53
- -
0.62
1.17
8.32
9.77
12.54
14.32
17.55
Return on Capital (%)
6.03
- -
- -
-4.75
8.39
-48.64
- -
2.07
-0.86
1.71
2.9
2.95
1.82
1.25
Return on Common Equity (%)
19.5
-10.98
0.18
-7.87
38.22
13.32
-20
8.46
-2.74
22.13
16.48
35.43
23.57
32.69

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
258,371
348,722
339,954
LT Borrowings
83,100
- -
- -
LT Finance Leases
18,147
17,778
17,080
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
248,395
273,650
254,276

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
400,913
411,951
423,262
Cash, Cash Equivalents & STI
89,526
84,669
103,337
Accounts Receivable, Net
137,548
141,340
141,692
Inventories
156,575
161,530
156,964
Total Current Liabilities
456,732
563,205
532,554
Payables & Accruals
- -
- -
- -
ST Debt
258,371
348,722
339,954
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.63%
14.3%
14.05%
Free Cash Flow
-118.96%
33.03%
75.23%
Net Income, GAAP
-683.12%
-163.91%
-6.57%
Sales/Revenue/Turnover
4.64%
4.55%
9.22%
Total Cash Common Dividend
22.11%
3.34%
7.9%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
222,982
214,733
226,489
223,506
887,710
2025
239,530
228,383
244,088
257,565
969,565
2026
243,221
266,470
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
178
412
181
105.15
874
2025
144
57
309.98
328.81
841
2026
298.7
281
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.77
349.53
-117.97
- -
239.66
2025
- -
- -
-1.66
- -
266.32
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kyung-Ha Lee
Full Time Employees
128
Sector
Health technology
Industry
Pharmaceuticals: major
Address
JW Gwacheon Tower Gwacheon-si GY South Korea 13840
IPO Date
Jul 31, 2007
Website
jw-holdings.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
JW Holdings Corporation operates as a holding company for healthcare businesses, primarily engaged in the development, manufacturing and export of pharmaceuticals, medical devices, infusion solutions and related products through subsidiaries including JW Pharmaceutical, JW Shinyak, JW Life Science and JW Medical; core offerings encompass antibiotics such as carbapenems including the generic Imipenem, antifungal agents, hyperlipidemia drugs, electrolyte additives, amino acid solutions, gastrointestinal agents, wound care products, eye care treatments, liver disease therapies, cold medicines, active pharmaceutical ingredients, oral and topical analgesics, cosmetics like hair dye and beauty care items, non-PVC infusion containers, tubes and bags, 3D digital mammography equipment, MRI and CT scanners, sterilizers, operating room equipment, infant care systems and health supplements. The company conducts operations in South Korea, the United States, Japan, China and other international markets. Founded in 1945 and headquartered in Gwacheon-si, South Korea, JW Holdings recently advanced its anti-cancer drug development through a collaboration between JW Pharmaceutical and U.S.-based Tempus AI utilizing clinical data and organoids, integrated its AI platforms Jewelry and Clover with expanded capabilities, progressed STAT3 inhibitor JW2286 as a first-in-class innovative drug, achieved positive Phase 3 data for a gout treatment with IND approvals in five Asian countries and secured research funding for novel compounds targeting XBP1s and Wnt signaling pathways.